NVS — Novartis AG
$151.12-3.30%
Last close: · regular session
Last 60 sessions
NVS closed at $151.12 (-3.30%) on Oct 23, 2026. Float: 1.8B shares. Latest SEC filing: 424B5 on Mar 17, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for NVS in the TickerWise workspace.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Country: CH
- Exchange: NYSE
- Employees: 75,883
- Website: https://www.novartis.com
Latest SEC filings for NVS
Latest NVS news
- Novartis gains EC approval of Cosentyx for polymyalgia rheumatica Read article
- Novartis halts mid-stage trial for kidney drug, Fabhalta, in lupus nephritis Read article
- Novartis leprosy drug Lamprene now more easily available Read article
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS Read article
- NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido Read article
- US FDA expands use of Novartis drug for chronic skin condition Read article
- Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026 Read article
- Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.